Taysha Gene Therapies, Inc.
TSHA
$5.95
-$0.04-0.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -32.27% | 3.42% | 17.28% | -36.36% | -37.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.27% | 3.42% | 17.28% | -36.36% | -37.09% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -32.27% | 3.42% | 17.28% | -36.36% | -37.09% |
| SG&A Expenses | 24.44% | 17.85% | 16.98% | 20.74% | 12.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.11% | 53.99% | 26.66% | 17.36% | 8.15% |
| Operating Income | -71.77% | -58.36% | -27.56% | -23.81% | -15.71% |
| Income Before Tax | -61.38% | -49.69% | -22.06% | -338.82% | 18.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.38% | -49.69% | -22.06% | -338.82% | 18.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.38% | -49.69% | -22.06% | -338.82% | 18.90% |
| EBIT | -71.77% | -58.36% | -27.56% | -23.81% | -15.71% |
| EBITDA | -72.70% | -59.26% | -28.08% | -24.39% | -16.23% |
| EPS Basic | -23.02% | -12.32% | 5.18% | -432.32% | 62.68% |
| Normalized Basic EPS | -33.63% | -21.27% | 0.41% | -1,558.26% | 66.61% |
| EPS Diluted | -23.02% | -12.32% | 5.18% | -432.32% | 62.68% |
| Normalized Diluted EPS | -33.63% | -21.27% | 0.41% | -1,558.26% | 66.61% |
| Average Basic Shares Outstanding | 31.07% | 32.45% | 27.76% | 26.15% | 37.87% |
| Average Diluted Shares Outstanding | 31.07% | 32.45% | 27.76% | 26.15% | 37.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |